Differences between thyrotropin receptor antibody bioactivity and inhibition of 125I-bovine thyrotropin binding.

Thyrotropin (TSHR) receptor antibodies that bind to the TSHR without stimulating the TSHR have been identified with a direct binding assay. Moreover, TSHR antibodies that exhibit thyroid epithelial cell stimulation without inhibition of 125I-bovine thyrotropin (bTSH) binding and vice versa have been described. These data suggest that stimulation or blocking of the TSHR by stimulating (TSAB) or blocking (TSBAB) TSHR antibodies could be possible without detectable bTSH-displacement activity. However, to date, possible differences between TSAB or TSBAB activity and inhibition of 125I-bTSH binding have not been systematically investigated. Therefore we compared inhibition of 125I-bTSH binding and TSAB or TSBAB activity of sera from 113 patients with Graves' disease treated with antithyroid drugs. To exclude the different assay conditions of previous investigations as possible confounding factors, we determined TSAB or TSBAB and inhibition of 125I-bTSH binding (TBIIW) with the same Chinese hamster ovary (CHO) cells expressing the human TSHR. Furthermore inhibition of 125I-bTSH binding was also determined as thyrotropin-binding inhibitory immunoglobulin (TBII) with solubilized porcine thyroid membranes (TRAK, Brahms, Berlin Germany) and the highly sensitive recombinant human TSH receptor assay (hTRAK, Brahms, Berlin Germany). Only 78% (54/69) of TSAB-positive and 78% (21/27) of TSBAB-positive sera detected with JP26 cells exhibit inhibition of 125I-bTSH binding measured as TBII or TBIIW. Furthermore, 59% (10/17) of sera without TSAB and TSBAB activity revealed inhibition of 125I-bTSH binding measured as TBII or TBIIW. We found significant differences between TSHR bioactivities (TSAB or TSBAB) and inhibition of 125I-bTSH binding. Moreover, there was no agreement between the detectable TSHR bioactivities (TSAB or TSBAB) and their detectable inhibition of 125I-bTSH binding. Therefore, it is very likely that TSH displacement by TSHR antibodies and stimulation or blocking of the TSHR by TSHR antibodies are different functions that do not need to occur together.

[1]  B. Rapoport,et al.  A direct binding assay for thyrotropin receptor autoantibodies. , 1999, Thyroid : official journal of the American Thyroid Association.

[2]  B. Smith,et al.  The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor. , 1999, The Journal of clinical endocrinology and metabolism.

[3]  K. Kuma,et al.  Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. , 1999, Thyroid : official journal of the American Thyroid Association.

[4]  K. Usadel,et al.  Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. , 1999, The Journal of clinical endocrinology and metabolism.

[5]  B. Rapoport,et al.  The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies , 1998 .

[6]  I. Huhtaniemi,et al.  Recombinant forms of rat and human luteinizing hormone and follicle-stimulating hormone; comparison of functions in vitro and in vivo. , 1998, The Journal of endocrinology.

[7]  Harris Pe,et al.  Potential pathogenicity of autoantibodies to thyrotropin receptor in treated, euthyroid patients with Graves' disease , 1998 .

[8]  R. Paschke,et al.  Deletions in the Third Intracellular Loop of the Thyrotropin Receptor , 1998, The Journal of Biological Chemistry.

[9]  A. Kung,et al.  A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy. , 1998, The Journal of clinical endocrinology and metabolism.

[10]  M. Meldal,et al.  Synthetic hFSH peptide constructs in the evaluation of previous studies on the hFSH receptor interaction , 1997, Journal of peptide science : an official publication of the European Peptide Society.

[11]  B. Rapoport,et al.  The human thyrotropin (TSH) receptor in a TSH binding inhibition assay for TSH receptor autoantibodies. , 1997, The Journal of clinical endocrinology and metabolism.

[12]  J. Parma,et al.  Constitutive activation of the TSH receptor by spontaneous mutations affecting the N‐terminal extracellular domain , 1997, FEBS letters.

[13]  N. Amino,et al.  Subtypes of anti-TSH receptor antibodies classified by various assays using CHO cells expressing wild-type or chimeric human TSH receptor. , 1997, Thyroid : official journal of the American Thyroid Association.

[14]  A. Allgeier,et al.  Specific activation of the thyrotropin receptor by trypsin , 1996, Molecular and Cellular Endocrinology.

[15]  S. Swillens,et al.  Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. , 1996, The Journal of clinical endocrinology and metabolism.

[16]  S. Swillens,et al.  Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. , 1995, Molecular endocrinology.

[17]  J. Meininger,et al.  Assessing agreement between clinical measurement methods. , 1995, Heart & lung : the journal of critical care.

[18]  R. Paschke,et al.  Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. , 1994, The Journal of clinical endocrinology and metabolism.

[19]  A. Pinchera,et al.  Detection of antibodies blocking thyrotropin effect using Chinese hamster ovary cells transfected with the cloned human TSH receptor , 1994, Journal of endocrinological investigation.

[20]  T. Lemarchand-Béraud,et al.  Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases. , 1994, European journal of endocrinology.

[21]  P. Carayon,et al.  Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. , 1994, The Journal of clinical endocrinology and metabolism.

[22]  J. Parma,et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas , 1993, Nature.

[23]  M. Derwahl,et al.  Measurement of stimulating TSH receptor antibodies in sera of patients with Graves' disease by a recombinant TSH receptor bioassay. , 2009, Experimental and clinical endocrinology.

[24]  S. Costagliola,et al.  Recombinant TSH-receptor for determination of TSH-receptor-antibodies. , 2009, Experimental and clinical endocrinology.

[25]  S. Swillens,et al.  Binding assay for thyrotropin receptor autoantibodies using the recombinant receptor protein. , 1992, The Journal of clinical endocrinology and metabolism.

[26]  L. Cyr,et al.  Measures of clinical agreement for nominal and categorical data: the kappa coefficient. , 1992, Computers in biology and medicine.

[27]  A Donner,et al.  Application of the McNemar test to non-independent matched pair data. , 1991, Statistics in medicine.

[28]  V. Wheaton,et al.  Domains specifying thrombin–receptor interaction , 1991, Nature.

[29]  S. Filetti,et al.  The biological activity of bovine and human thyrotropin is differently affected by trypsin treatment of human thyroid cells: thyroid-stimulating antibody is related to human thyrotropin. , 1991, The Journal of clinical endocrinology and metabolism.

[30]  H. Imura,et al.  A synthetic oligopeptide derived from human thyrotropin receptor sequence binds to Graves' immunoglobulin and inhibits thyroid stimulating antibody activity but lacks interactions with TSH. , 1991, Biochemical and biophysical research communications.

[31]  J. Wess,et al.  Antagonist binding profiles of five cloned human muscarinic receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.

[32]  H. Ogura,et al.  Coexistence of autoantibody to human thyrotropin (TSH) and autoanti-idiotypic antibody to antihuman TSH antibody in a case with simple goiter. , 1990, The Journal of clinical endocrinology and metabolism.

[33]  M. Parmentier,et al.  Use of the recombinant human thyrotropin receptor (TSH-R) expressed in mammalian cell lines to assay TSH-R autoantibodies , 1990, Molecular and Cellular Endocrinology.

[34]  M. Parmentier,et al.  Stable expression of the human TSH receptor in CHO cells and characterization of differentially expressing clones. , 1990, Biochemical and biophysical research communications.

[35]  A. Pinchera,et al.  Incidence of antibodies blocking thyrotropin effect in vitro in patients with euthyroid or hypothyroid autoimmune thyroiditis. , 1990, The Journal of clinical endocrinology and metabolism.

[36]  K. Burman,et al.  Antithyrotropin antibodies in the sera of Graves' disease patients. , 1985, The Journal of clinical endocrinology and metabolism.